WO2016108489A1 - Nouveau composé de ruthénium et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif - Google Patents
Nouveau composé de ruthénium et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif Download PDFInfo
- Publication number
- WO2016108489A1 WO2016108489A1 PCT/KR2015/014074 KR2015014074W WO2016108489A1 WO 2016108489 A1 WO2016108489 A1 WO 2016108489A1 KR 2015014074 W KR2015014074 W KR 2015014074W WO 2016108489 A1 WO2016108489 A1 WO 2016108489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- formula
- tumor
- compound
- ruthenium
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 113
- 201000011510 cancer Diseases 0.000 title claims abstract description 84
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 42
- 239000004480 active ingredient Substances 0.000 title claims abstract description 17
- 150000003304 ruthenium compounds Chemical class 0.000 title description 9
- XISQJDPDCQYNKD-UHFFFAOYSA-N [Ru].N1=CNC2=C1C=CC=C2 Chemical compound [Ru].N1=CNC2=C1C=CC=C2 XISQJDPDCQYNKD-UHFFFAOYSA-N 0.000 claims abstract description 52
- URWPISUFSXLXKZ-UHFFFAOYSA-N C1=CC=CC=2C3=CC=CC=C3C=CC12.[Ru] Chemical compound C1=CC=CC=2C3=CC=CC=C3C=CC12.[Ru] URWPISUFSXLXKZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 137
- 150000001875 compounds Chemical class 0.000 claims description 94
- 150000003839 salts Chemical class 0.000 claims description 57
- 239000007787 solid Substances 0.000 claims description 35
- 230000004900 autophagic degradation Effects 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 27
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 26
- 230000001093 anti-cancer Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 229910052707 ruthenium Inorganic materials 0.000 claims description 23
- 230000006907 apoptotic process Effects 0.000 claims description 22
- 206010017758 gastric cancer Diseases 0.000 claims description 22
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 21
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 21
- 201000011549 stomach cancer Diseases 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 19
- 108090000695 Cytokines Proteins 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 210000004392 genitalia Anatomy 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 229910015892 BF 4 Inorganic materials 0.000 claims description 12
- 229910020366 ClO 4 Inorganic materials 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 12
- 229910021115 PF 6 Inorganic materials 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 208000014018 liver neoplasm Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 9
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 206010038038 rectal cancer Diseases 0.000 claims description 9
- 201000001275 rectum cancer Diseases 0.000 claims description 9
- 229910052709 silver Inorganic materials 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 201000010175 gallbladder cancer Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 6
- 206010034299 Penile cancer Diseases 0.000 claims description 6
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 6
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 6
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 230000005907 cancer growth Effects 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 201000000349 mediastinal cancer Diseases 0.000 claims description 6
- 206010027191 meningioma Diseases 0.000 claims description 6
- 208000018280 neoplasm of mediastinum Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000037965 uterine sarcoma Diseases 0.000 claims description 6
- 206010046885 vaginal cancer Diseases 0.000 claims description 6
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 6
- 206010061424 Anal cancer Diseases 0.000 claims description 5
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 5
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 5
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 5
- 201000011165 anus cancer Diseases 0.000 claims description 5
- 210000000038 chest Anatomy 0.000 claims description 5
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000003175 male breast cancer Diseases 0.000 claims description 5
- 208000010907 male breast carcinoma Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000037968 sinus cancer Diseases 0.000 claims description 5
- 208000006678 Abdominal Neoplasms Diseases 0.000 claims description 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 4
- 201000009636 cerebral lymphoma Diseases 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 201000000374 female urethral cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 208000037830 nasal cancer Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 210000004248 oligodendroglia Anatomy 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000025426 neoplasm of thorax Diseases 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 201000003957 thoracic cancer Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 102100032702 Protein jagged-1 Human genes 0.000 description 50
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 37
- 229940125797 compound 12 Drugs 0.000 description 37
- 238000005481 NMR spectroscopy Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 239000003446 ligand Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 0 CC[C@@](C)CC1C(C*2)[C@@]2C2C1CC2 Chemical compound CC[C@@](C)CC1C(C*2)[C@@]2C2C1CC2 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- 229960004316 cisplatin Drugs 0.000 description 16
- 229940125758 compound 15 Drugs 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 13
- 229910052751 metal Inorganic materials 0.000 description 13
- 239000002184 metal Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000007522 mineralic acids Chemical class 0.000 description 12
- 150000007524 organic acids Chemical class 0.000 description 12
- 229940126214 compound 3 Drugs 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 239000000314 lubricant Substances 0.000 description 11
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 10
- 150000002678 macrocyclic compounds Chemical class 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101001097814 Homo sapiens 40S ribosomal protein S21 Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 239000000829 suppository Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 8
- FASWKGOEFGHELG-UHFFFAOYSA-N 4-[2-[5-(2-pyridin-4-ylethynyl)furan-2-yl]ethynyl]pyridine Chemical compound N1=CC=C(C=C1)C#CC=1OC(=CC=1)C#CC1=CC=NC=C1 FASWKGOEFGHELG-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- -1 L1 Chemical compound 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 239000000370 acceptor Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 102100037710 40S ribosomal protein S21 Human genes 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 6
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 6
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000003125 aqueous solvent Substances 0.000 description 6
- 235000014121 butter Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 229950006191 gluconic acid Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000001361 intraarterial administration Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000001338 self-assembly Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 5
- 102100020814 Sequestosome-1 Human genes 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000002051 biphasic effect Effects 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000009422 growth inhibiting effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- WWRCMNKATXZARA-UHFFFAOYSA-N 1-Isopropyl-2-methylbenzene Chemical compound CC(C)C1=CC=CC=C1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 3
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 239000000022 bacteriostatic agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000000352 p-cymenyl group Chemical group C1(=C(C=C(C=C1)C)*)C(C)C 0.000 description 3
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000005469 synchrotron radiation Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- XTPMJIMUYNZFFN-UHFFFAOYSA-N 3,6-dibromophenanthrene Chemical compound C1=C(Br)C=C2C3=CC(Br)=CC=C3C=CC2=C1 XTPMJIMUYNZFFN-UHFFFAOYSA-N 0.000 description 2
- MQSMIIJCRWDMDL-UHFFFAOYSA-N 3,6-dipyridin-4-yl-1,2,4,5-tetrazine Chemical compound C1=NC=CC(C=2N=NC(=NN=2)C=2C=CN=CC=2)=C1 MQSMIIJCRWDMDL-UHFFFAOYSA-N 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N CC(C)c1ccc(C)cc1 Chemical compound CC(C)c1ccc(C)cc1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010083698 Chemokine CCL26 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000037564 High-grade astrocytoma Diseases 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101150068514 RPS21 gene Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 208000022080 low-grade astrocytoma Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 108010045758 lysosomal proteins Proteins 0.000 description 2
- 201000005831 male reproductive organ cancer Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 208000025440 neoplasm of neck Diseases 0.000 description 2
- LYGJENNIWJXYER-FIBGUPNXSA-N nitromethane-d3 Chemical compound [2H]C([2H])([2H])[N+]([O-])=O LYGJENNIWJXYER-FIBGUPNXSA-N 0.000 description 2
- 208000023983 oral cavity neoplasm Diseases 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000005424 photoluminescence Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LAXRNWSASWOFOT-UHFFFAOYSA-J (cymene)ruthenium dichloride dimer Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Ru+2].[Ru+2].CC(C)C1=CC=C(C)C=C1.CC(C)C1=CC=C(C)C=C1 LAXRNWSASWOFOT-UHFFFAOYSA-J 0.000 description 1
- KGKAYWMGPDWLQZ-UHFFFAOYSA-N 1,2-bis(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1CBr KGKAYWMGPDWLQZ-UHFFFAOYSA-N 0.000 description 1
- UYYRNDXXSOFUDM-UHFFFAOYSA-N 1,3-bis(bromomethyl)benzene Chemical compound BrCC1=CC=CC(CBr)=C1.BrCC1=CC=CC(CBr)=C1 UYYRNDXXSOFUDM-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical compound BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 1
- KCSZKGMHDFZUEV-UHFFFAOYSA-N 1-phenylsiline Chemical compound C1=CC=CC=[Si]1C1=CC=CC=C1 KCSZKGMHDFZUEV-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- USEMUJJHZMGJIX-UHFFFAOYSA-N 2-phenyl-1H-benzimidazole Chemical compound C1(=CC=CC=C1)C=1NC2=C(N1)C=CC=C2.C2(=CC=CC=C2)C=2NC1=C(N2)C=CC=C1 USEMUJJHZMGJIX-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- CLRPXACRDTXENY-UHFFFAOYSA-N 3-ethynylpyridine Chemical compound C#CC1=CC=CN=C1 CLRPXACRDTXENY-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 101710129634 Beta-nerve growth factor Proteins 0.000 description 1
- UAYVIXWWXWAGDG-UHFFFAOYSA-N BrCC1=CC=C(C=C1)CBr.BrCC1=CC=C(C=C1)CBr Chemical compound BrCC1=CC=C(C=C1)CBr.BrCC1=CC=C(C=C1)CBr UAYVIXWWXWAGDG-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- WHNGPXQYYRWQAS-UHFFFAOYSA-N CC(C)C1C=CC(C)CC1 Chemical compound CC(C)C1C=CC(C)CC1 WHNGPXQYYRWQAS-UHFFFAOYSA-N 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N CC(C)C1CCC(C)CC1 Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000611240 Homo sapiens Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910019854 Ru—N Inorganic materials 0.000 description 1
- 238000004639 Schlenk technique Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- QMPSUPWBJMOGPS-UHFFFAOYSA-N [Ru].CC(C)C1=CC=C(C)C=C1 Chemical group [Ru].CC(C)C1=CC=C(C)C=C1 QMPSUPWBJMOGPS-UHFFFAOYSA-N 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000009166 antihormone therapy Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001109 autodigestive effect Effects 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000004908 autophagic flux Effects 0.000 description 1
- 230000007455 autophagic response Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N naphthoquinone group Chemical group C1(C=CC(C2=CC=CC=C12)=O)=O FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- 201000010762 nasal cavity neoplasm Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005287 template synthesis Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
- C07C13/573—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with three six-membered rings
- C07C13/60—Completely or partially hydrogenated phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
Definitions
- the present invention relates to novel quaternary arene-ruthenium compounds, phenanthrene-ruthenium compounds, benzimidazole-ruthenium and pharmaceutical compositions for the prevention or treatment of cancer diseases containing them as active ingredients.
- anti-autophagy proteins such as B-cell lymphoma 2 (Bcl-2), picasedelta (PKC ⁇ ), and tissue transglutaminase 2 (TG2).
- Bcl-2 B-cell lymphoma 2
- PLC ⁇ picasedelta
- TG2 tissue transglutaminase 2
- Induction of autophagy by inhibition of (anti-autophagic proteins) may lead to autophagic cell death of some apoptosis-resistant cancers (eg, breast and pancreatic cancer). Proved.
- some cases of inhibition of autophagy in cancer cells may increase the susceptibility of cancer to a variety of therapies such as DNA damaging agents, antihormone therapies and radiation therapy. Showed therapeutic benefit.
- the induction or inhibition of autophagy may provide therapeutic benefits for the patient, so the design and synthesis of autophagy modulators can be used as a new therapeutic strategy for cancer. have.
- the metal pharmaceutical field is rapidly becoming popular through the therapeutic application of metal-based drugs.
- Platinum complexes, cisplatin, carboplatin and oxoplatin, are known as the most effective chemoherapeutic agents.
- cisplatin has serious side effects of nephrotoxicity and neurotoxicity.
- the present invention seeks to provide novel quaternary arene-ruthenium compounds, phenanthrene-ruthenium compounds, benzimidazole-ruthenium compounds and their use for anticancer treatment.
- the present invention provides an arene-ruthenium compound represented by the following formula (1) or (2) or a pharmaceutically acceptable salt thereof:
- each of X is independently trifluoromethylsulfonate (OTf), nitrate (NO 3 ), toluene-4-sulfonate (toulene-4-sulfonate, OTs), Methanesulfonate (OMs), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO; Is a single bond or a double bond,
- a nitrogen atom in the aromatic ring of Formula 4 or 5 and ruthenium of Formulas 3a to 3c are respectively bonded, and X is separated to form a compound of Formula 1 or 2.
- the present invention provides a pharmaceutical composition for preventing or treating cancer diseases, characterized in that it comprises an arene-ruthenium compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt thereof.
- the present invention provides a phenanthrene-ruthenium compound represented by Formula 6 or a pharmaceutically acceptable salt thereof:
- A is independently OTf (trifluoromethylsulfonate), nitrate (NO 3 ), OTs (toluene-4-sulfonate), OMs (methanesulfonate), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO,
- A is separated from the compound of Formula 7, Formula 8 or Formula 9 and ruthenium and a nitrogen atom in the aromatic ring of Formula 10 combine to form a compound of Formula 6.
- the present invention also provides a pharmaceutical composition for preventing or treating cancer diseases containing the phenanthrene-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a benzimidazole-ruthenium compound represented by the following formula (11) or a pharmaceutically acceptable salt thereof:
- X may be halogen
- the present invention also provides a pharmaceutical composition for treating or preventing cancer diseases containing the benzimidazole-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the quaternary arene-ruthenium compound according to the present invention showed better anticancer activity compared to known anticancer drugs cisplatin and doxorubicin, and particularly exhibited excellent anticancer activity by strongly inducing autophagy at low concentration in colon cancer cells.
- the phenanthrene-ruthenium compound according to the present invention inhibits Akt-mTOR signaling pathway and increases caspase activity in cancer cells, thereby inhibiting cancer cell proliferation by activating autophagy of cancer cells and inducing apoptosis cell death. It showed excellent anticancer activity, and showed excellent anticancer activity even at a lower concentration than conventional anticancer agents.
- the novel benzimidazole-ruthenium compound according to the present invention is a macrophage cell that secretes cytokines, a signaling molecule that regulates the physiological activity of cells. Secrete cytokines that form tumors As it has been confirmed that the effect of inhibiting the growth of cancer cells by increasing the secretion of cytokines that inhibit and increase the anticancer effect, the novel ruthenium compound of the present invention can be usefully used for the prevention or treatment of cancer diseases.
- FIG. 1 is a schematic diagram for preparing Compounds 1 to 6 according to the present invention.
- FIG. 2 is a result of the nitromethane -D 3 (Nitromethane-D 3, CD 3 NO 2)
- the 1 H-NMR (nuclear magnetic resonance, NMR) spectra and the results of FIG. 2 is recorded in a compound L1, B in FIG. 2 is the result of compound 1 according to the present invention.
- ESI-MS electrospray ionization mass spectrometry
- FIG. 4 shows UV / Vis spectra results
- a in FIG. 4 is a result of compounds 1 to 3 according to the present invention
- b in FIG. 4 is a result of compounds 4 to 6 according to the present invention
- C in Figure 4 is the result of the receptor (A1 to A3) and the donors (L1 and L2).
- Figure 5 a is an X-ray crystal structure (X-ray crystal structure) of Compound 1 according to the present invention
- b in Figure 5 is a space-filling model (CPK model) according to the present invention
- the structure of Compound 1 is shown (green: ruthenium, red: oxygen, blue: nitrogen and grey: carbon).
- FIG. 6 is a graph showing the anticancer effect of Compound 3 and Compound 6 according to the present invention in colon cancer cells.
- FIG. 7 is a graph showing the child action according to the concentration change of Compound 3 and Compound 6 according to the present invention in colon cancer cells.
- ESI-MS electrospray ionization mass spectrometry
- FIG. 10 shows apoptosis effect by Compound 12 after treatment with 0, 1, 5, 10 and 20 ⁇ M Compound 12 for 24 hours in AGS and COS7 cell lines.
- FIG. 10A shows the relative autophagy activity following Compound 12 treatment.
- 10B shows the results of apoptosis apoptosis according to Compound 12 treatment.
- FIG. 11 is a result of confirming apoptosis control process by Compound 12
- Figure 11A is a result of confirming the LC3 and p62 protein levels in the autophagy response induced by Compound 12
- Figure 11B is Akt and COS7 cell lines in Akt and It is the result of confirming the apoptosis and autophagy effect of the compound 12 by confirming the degree of mTOR expression.
- Figure 13 shows the results confirming the growth inhibitory activity of compound 12 pre-cultured in AGS cell culture medium.
- FIG. 14 shows the HR-ESI-MS spectra calculated value (blue) and experimental value (red) of lutenacycle [1M-Cl] + .
- Figure 16 shows the results of screening genes differentially expressed by RT-PCR method using GeneFishing DEG system in AGS cells treated with 20 ⁇ M cisplatin (Cp) and 10 ⁇ M benzimidazole-ruthenium compound 15 for 24 hours.
- 19 is a result of treating 20 ⁇ M benzimidazole-ruthenium compound 15 in AGS cells for 0, 12, 24 and 48 hours and confirming the loss of growth inhibitory activity of benzimidazole-ruthenium compound 15 over time.
- the present invention provides an arene-ruthenium compound represented by the following Chemical Formula 1 or 2 or a pharmaceutically acceptable salt thereof.
- each of X is independently trifluoromethylsulfonate (OTf), nitrate (NO 3 ), toluene-4-sulfonate (toulene-4-sulfonate, OTs), Methanesulfonate (OMs), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO; Is a single bond or a double bond,
- a nitrogen atom in the aromatic ring of Formula 4 or 5 and ruthenium of Formulas 3a to 3c are respectively bonded, and X is separated to form a compound of Formula 1 or 2.
- the present invention is characterized in that the nitrogen atom in the aromatic ring of the formula (4) or (5) and ruthenium of the formula (3c) is bonded, and X is separated to form a compound of the formula (1) or (2), or It provides a pharmaceutically acceptable salt thereof.
- X is each independently trifluoromethylsulfonate (OTf), nitrate (NO 3 ), toluene-4-sulfonate (toulene-4-sulfonate, OTs), methanesulfonate (methanesulfonate, OMs), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO, wherein Is a single bond or a double bond,
- the arene-ruthenium compound of the present invention represented by Chemical Formula 1 or 2 may be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as a salt.
- the inorganic acid and organic acid may be used as the free acid, and hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid, etc. may be used as the inorganic acid, and citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, and methanesulfonic acid may be used as the organic acid.
- Acetic acid glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, aspartic acid, and the like can be used.
- hydrochloric acid may be used as the inorganic acid
- methanesulfonic acid may be used as the organic acid.
- the arene-ruthenium compound of the present invention represented by Formula 1 or 2 of the present invention includes not only pharmaceutically acceptable salts, but also all salts, hydrates, and solvates that can be prepared by conventional methods.
- the addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving a compound of Formula 1 or Formula 2 in a water miscible organic solvent, such as acetone, methanol, ethanol, or acetonitrile, and adding an excess of an organic acid. It may be prepared by addition or precipitation of an acidic aqueous solution of an inorganic acid followed by precipitation or crystallization. The solvent or excess acid may then be evaporated and dried in this mixture to obtain an addition salt or the precipitated salt may be prepared by suction filtration.
- a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- FIG. 1 A schematic diagram of preparation of the arene-ruthenium compounds 1 to 6 according to the present invention is shown in FIG. 1.
- the quaternary arene-ruthenium compound of Chemical Formula 1 is represented by [Ru 2 ( ⁇ 4 -C 2 O 4 ) ( ⁇ 6 -p- i PrC 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 ( A1 ), [Ru 2 (dobq) ( ⁇ 6 -p -Pr i C 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 ( A2 ) of formula 3b or [Ru of formula 3c 2 (donq) ( ⁇ 6 -p-Pr i C 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 ( A3 ) and 3,6-di (pyridine), the dipyridyl donor of formula (4) Nitrogen solution containing an equivalent mole of 4-yl) -1,2,4,5-tetraazine (3,6-di (pyridin-4-
- the quaternary arene-ruthenium compound of Chemical Formula 2 may be prepared by [Ru 2 ( ⁇ - ⁇ 4 -C 2 O 4 ) ( ⁇ 6 -p- i PrC 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 of Chemical Formula 3a.
- the new arene-ruthenium compounds prepared as described above are prepared by infrared spectroscopy, nuclear magnetic resonance spectra, mass spectroscopy, liquid chromatography, X-ray structure determination, photoluminescence, and elemental analysis calculations and actual measurements of representative compounds. The molecular structure can be confirmed by comparison.
- the four-nuclear arene-ruthenium compound of Formula 1 or 2 according to the present invention induces autophagy in human AGS (gastric cancer) and HCT-15 (colon cancer) cell lines, thereby inducing It shows excellent anticancer activity by inducing cell death and can be used as an active ingredient of anticancer agent.
- the present invention provides a pharmaceutical composition for preventing or treating cancer diseases, comprising the arene-ruthenium compound represented by the following Chemical Formula 1 or 2 or a pharmaceutically acceptable salt thereof.
- each of X is independently trifluoromethylsulfonate (OTf), nitrate (NO 3 ), toluene-4-sulfonate (toulene-4-sulfonate, OTs), Methanesulfonate (OMs), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO; Is a single bond or a double bond,
- a nitrogen atom in the aromatic ring of Formula 4 or 5 and ruthenium of Formulas 3a to 3c are respectively bonded, and X is separated to form a compound of Formula 1 or 2.
- the arene-ruthenium compound is a nitrogen atom in the aromatic ring of formula (4) or (5) and ruthenium of the formula (3c) is bonded, the following X is separated to form a compound of formula (1) or (2) or Provided is a therapeutic pharmaceutical composition.
- X is each independently trifluoromethylsulfonate (OTf), nitrate (NO 3 ), toluene-4-sulfonate (toulene-4-sulfonate, OTs), methanesulfonate (methanesulfonate, OMs), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO, wherein Is a single bond or a double bond,
- the pharmaceutical composition for preventing or treating cancer diseases containing the arene-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient is based on the arene-ruthenium compound or 100 parts by weight of the pharmaceutical composition.
- a pharmaceutically acceptable salt may be included in an amount of 0.01 to 90 parts by weight, 0.1 to 90 parts by weight, 1 to 90 parts by weight, or 10 to 90 parts by weight, but is not limited thereto. It may vary depending on the degree.
- the pharmaceutical composition for preventing or treating cancer diseases containing the arene-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient includes a carrier, an excipient, a disintegrant, a sweetener, a coating agent, an expanding agent, It may further comprise one or more adjuvants selected from the group consisting of lubricants, glidants, flavors, antioxidants, buffers, bacteriostatics, diluents, dispersants, surfactants, binders and lubricants.
- the carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, capsules.
- solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the composition.
- excipients such as starch, calcium carbonate, sucrose or lactose, gelatin and the like
- lubricants such as magnesium styrate and talc may also be used.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- Witsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used as the base material of the suppository.
- the formulation of the pharmaceutical composition for preventing or treating cancer containing the arene-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient is granules, powders, coated tablets, tablets, pills, It may be selected from the group consisting of capsules, suppositories, gels, syrups, juices, suspensions, emulsions, drops or solutions.
- the pharmaceutical composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, nasal, inhaled, topical, rectal, oral, intraocular or intradermal Via the route can be administered to the subject in a conventional manner.
- Preferred dosages of the pharmaceutical composition for preventing or treating cancer containing the arene-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient include the condition and weight of the patient, the type and extent of the disease, the form of the drug, the route of administration and It may vary depending on the time period and may be appropriately selected by those skilled in the art. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 1,000 mg / kg, specifically 0.1 to 1,000 mg / kg, more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several times, thereby not limiting the scope of the invention.
- the 'subject' may be a mammal including a human, but is not limited thereto.
- the cancer may be a solid cancer, and more specifically, the arene-ruthenium compound of Formula 1 or 2 according to the present invention may be used for gastric cancer, colorectal cancer, or brain tumor.
- Brain tumor Low-grade astrocytoma, High-grade astrocytoma, Pituitary adenoma, Meningioma, CNS lymphoma, Oligodendroglioma, Two cranial Craniopharyngioma, Ependymoma, Brain stem tumor, Head & Neck tumor, Larygeal cancer, Oropgaryngeal cancer, Nasal cavity / Sinus cancer PNS tumor, Nasopharyngeal tumor, Salivary gland tumor, Hypoharyngeal cancer, Thyroid cancer, Oral cavity tumor, Chest tumor, Small cell lung cancer, Small cell lung cancer cell lung cancer), non-small cell Non small cell lung cancer, Thymoma, Mediastinal tumor, Esophageal cancer, Breast cancer, Male
- the present invention also provides a phenanthrene-ruthenium compound represented by the following formula (6) or a pharmaceutically acceptable salt thereof:
- A is independently OTf (trifluoromethylsulfonate), nitrate (NO 3 ), OTs (toluene-4-sulfonate), OMs (methanesulfonate), Cl, Br, I, BF 4 , PF 6 , ClO 4 , CH 3 COO or CF 3 COO,
- A is separated from the compound of Formula 7, Formula 8 or Formula 9 and ruthenium and a nitrogen atom in the aromatic ring of Formula 10 combine to form a compound of Formula 6.
- the phenanthrene-ruthenium compound represented by the formula (6) is phenanthrene-ruthenium compound or a pharmaceutical thereof, wherein A is separated from the compound of the formula (8) and the nitrogen atom in the aromatic ring of the formula (10) is bonded It is possible to provide an acceptable salt.
- the phenanthrene-ruthenium compound of the present invention may be used in the form of a pharmaceutically acceptable salt, and acid salts formed by the pharmaceutically acceptable free acid are useful as salts.
- the inorganic acid and organic acid may be used as the free acid, and hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid, etc. may be used as the inorganic acid, and citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, and methanesulfonic acid may be used as the organic acid.
- Acetic acid glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, aspartic acid, and the like can be used.
- hydrochloric acid may be used as the inorganic acid
- methanesulfonic acid may be used as the organic acid.
- the phenanthrene-ruthenium compound of the present invention includes not only pharmaceutically acceptable salts, but also all salts, hydrates, and solvates that can be prepared by conventional methods.
- the addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound of Formula 6 in a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile and adding an excess of an organic acid or an inorganic acid. It can be prepared by adding an acidic aqueous solution of and then precipitating or crystallizing. The solvent or excess acid may then be evaporated and dried in this mixture to obtain an addition salt or the precipitated salt may be prepared by suction filtration.
- a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- phenanthrene-ruthenium compounds such as compounds 11 to 13 of the present invention are HCT-15 (rectal cancer cell line), SK-hep-1 (liver cancer cell line) and AGC (gastric cancer cell line) cells It inhibited Akt-mTOR signaling pathway and increased caspase activity, and showed excellent anticancer activity that inhibited cancer cell proliferation by inducing autophagy and apoptotic cell death of cancer cells, especially cisplatin in AGS cells.
- the present invention can provide a pharmaceutical composition for preventing or treating cancer diseases, which contains the phenanthrene-ruthenium compound of Formula 6 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the phenanthrene-ruthenium compound, or a pharmaceutically acceptable salt thereof, may exhibit anticancer activity by inducing autophagy and apoptosis of cancer cells.
- the pharmaceutical composition is 0.01 to 90 parts by weight, 0.1 to 90 parts by weight, 1 to 90 parts by weight or 10 to 90 parts by weight of the phenanthrene-ruthenium compound of Formula 6 based on 100 parts by weight of the pharmaceutical composition It may be included as part, but is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the degree of progression.
- the pharmaceutical composition is a carrier, excipient, disintegrant, sweetener, coating agent, expanding agent, lubricant, lubricant, flavoring agent, antioxidant, buffer, bacteriostatic agent, diluent, dispersant, surfactant, binder and It may further comprise one or more adjuvants selected from the group consisting of lubricants.
- the carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, capsules.
- solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the composition.
- excipients such as starch, calcium carbonate, sucrose or lactose, gelatin and the like
- lubricants such as magnesium styrate and talc may also be used.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- Witsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used as the base material of the suppository.
- the formulation of the pharmaceutical composition is a granule, powder, blood
- It may be selected from the group consisting of tablets, tablets, pills, capsules, suppositories, gels, syrups, juices, suspensions, emulsions, drops or solutions.
- the pharmaceutical composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, sternum, transdermal, nasal, inhaled, topical, rectal, oral, intraocular or It can be administered to a subject in a conventional manner via the intradermal route.
- the preferred dosage of the pharmaceutical composition may vary depending on the condition and weight of the patient, the type and extent of the disease, the form of the drug, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 1,000 mg / kg, specifically 0.1 to 1,000 mg / kg, more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several times, thereby not limiting the scope of the invention.
- the 'subject' may be a mammal including a human, but is not limited thereto.
- the cancer disease may be a solid cancer
- the solid cancer is brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, cerebral lymphoma, oligodendroma, intracranial tumor, epithelial cell tumor, brain stem tumor, Head and neck tumors, laryngeal cancer, oropharyngeal cancer, nasal / sinus cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, thyroid cancer, oral cancer, chest tumor, small cell lung cancer, non-small cell lung cancer, thymus cancer, mediastinal tumor, esophageal cancer, breast cancer, breast cancer, Abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, bladder cancer, kidney cancer, male genital tumor, penis cancer, prostate cancer, female gen
- the present invention also provides a benzimidazole-ruthenium compound represented by the following formula (11) or a pharmaceutically acceptable salt thereof:
- X may be halogen
- the benzimidazole-ruthenium compound may be a benzimidazole-ruthenium compound represented by Formula 12 or a pharmaceutically acceptable salt thereof:
- the benzimidazole-ruthenium compound of the present invention can be used in the form of a pharmaceutically acceptable salt, and acid salts formed by the pharmaceutically acceptable free acid are useful as salts.
- the inorganic acid and organic acid may be used as the free acid, and hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid, etc. may be used as the inorganic acid, and citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, and methanesulfonic acid may be used as the organic acid.
- Acetic acid glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, aspartic acid, and the like can be used.
- hydrochloric acid may be used as the inorganic acid
- methanesulfonic acid may be used as the organic acid.
- benzimidazole-ruthenium compounds of the present invention include not only pharmaceutically acceptable salts, but also all salts, hydrates, and solvates that can be prepared by conventional methods.
- the addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound of formula 11 in a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile and adding an excess of an organic acid or an inorganic acid. It can be prepared by adding an acidic aqueous solution of and then precipitating or crystallizing. The solvent or excess acid may then be evaporated and dried in this mixture to obtain an addition salt or the precipitated salt may be prepared by suction filtration.
- a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- the benzimidazole-ruthenium compound according to the present invention is made by reacting the same amount of a biphasic N, C-donor ligand having dichloro (p-cymene) ruthenium (II) dimer (RuPD) and phenyl-benzimidazole as shown in Scheme 1 below.
- a biphasic N, C-donor ligand having dichloro (p-cymene) ruthenium (II) dimer (RuPD) and phenyl-benzimidazole as shown in Scheme 1 below.
- it can be prepared by refluxing for 8 to 20 hours at 50 to 80 °C in the presence of methanol and NaOAc.
- the benzimidazole-ruthenium compound according to the present invention may be prepared by infrared spectroscopy, nuclear magnetic resonance spectra, mass spectroscopy, liquid chromatography, X-ray structure determination, photoluminescence measurement, and elemental analysis calculations and actual measurements of representative compounds. The molecular structure can be confirmed by comparison.
- the benzimidazole-ruthenium compound according to the present invention according to the present invention is AGS (gastric cancer cell line), HCT-15 (rectal cancer cell line) and SK-hep-1 (hepatic cancer cell line) It inhibits the proliferation of cells at low micromolar concentrations, and in particular affects macrophages, inhibits the secretion of cytokines that form tumors such as IFN ⁇ and exhibits anticancer effects such as RANTES and IGF-1. It can be used as an active ingredient of an anticancer agent because it shows the effect of inhibiting the growth of cancer cells by increasing the secretion of caine.
- the present invention provides a pharmaceutical composition for treating or preventing cancer diseases containing the benzimidazole-ruthenium compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a medical use of the benzimidazole-ruthenium compound for the manufacture of an anticancer agent.
- the present invention also provides a method for treating cancer disease, comprising administering the benzimidazole-ruthenium compound to a subject.
- the pharmaceutical composition is 0.01 to 90 parts by weight, 0.1 to 90 parts by weight, 1 to 90 parts by weight, or 10 to 10 parts by weight of the benzimidazole-ruthenium compound of Formula 11 based on 100 parts by weight of the pharmaceutical composition It may include 90 parts by weight, but is not limited thereto, and may vary depending on the type and progress of the patient's condition and disease.
- the pharmaceutical composition is a carrier, excipient, disintegrant, sweetener, coating agent, expanding agent, lubricant, lubricant, flavoring agent, antioxidant, buffer, bacteriostatic agent, diluent, dispersant, surfactant, binder and It may further comprise one or more adjuvants selected from the group consisting of lubricants.
- the carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, capsules.
- solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the composition.
- excipients such as starch, calcium carbonate, sucrose or lactose, gelatin and the like
- lubricants such as magnesium styrate and talc may also be used.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- Witsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used as the base material of the suppository.
- the formulation of the pharmaceutical composition in the group consisting of granules, powders, coated tablets, tablets, pills, capsules, suppositories, gels, syrups, juices, suspensions, emulsions, drops or solutions Can be selected.
- the pharmaceutical composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, sternum, transdermal, nasal, inhaled, topical, rectal, oral, intraocular or It can be administered to a subject in a conventional manner via the intradermal route.
- the preferred dosage of the pharmaceutical composition may vary depending on the condition and weight of the patient, the type and extent of the disease, the form of the drug, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 1,000 mg / kg, specifically 0.1 to 1,000 mg / kg, more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several times, thereby not limiting the scope of the invention.
- the 'subject' may be a mammal including a human, but is not limited thereto.
- the cancer disease may be a solid cancer, more specifically the benzimidazole-ruthenium compound of formula 11 according to the present invention is a brain tumor (Brain tumor), low-grade astrocytoma, High-grade astrocytoma, Pituitary adenoma, Meningioma, CNS lymphoma, Oligodendroglioma, Craniopharyngioma, Ependymoma, Brain stem tumor Brain stem tumor, Head & Neck tumor, Larygeal cancer, Oropgaryngeal cancer, Nasal cavity / PNS tumor, Nasopharyngeal tumor, Salivary cancer gland tumor, Hypopharyngeal cancer, Thyroid cancer, Oral cavity tumor, Chest Tumor, Small cell lung cancer, Non small cell lung cancer ), Thymic cancer (Thymoma) Mediastinal tumor, Esophageal cancer, Breast cancer, Breast cancer, Male breast cancer, Abdomen-pelvis tumor, Stomach cancer, Hepatom
- Receptor clips [Ru 2 ( ⁇ - ⁇ 4 -C 2 O 4 ) ( ⁇ 6 -p- i PrC 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 (A1), [Ru 2 (dobq) ( ⁇ 6 -p -Pr i C 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 (A2) and [Ru 2 (donq) ( ⁇ 6 -p-Pr i C 6 H 4 Me) 2 ] [O 3 SCF 3 ] 2 (A3) was synthesized under a dry nitrogen atmosphere according to the standard Schlenk technique.
- the data source was processed and converted using the HKL200 program.
- the structures were analyzed using direct methods and purified using full-matrix least-squares of F2 with appropriate software from the SHELXTL program package. UV-Vis spectra were recorded at Cary 100 Conc.
- Electrospray ionization mass spectrometry (ESI-MS) was performed for accurate analysis of the composition of the compounds according to the present invention.
- the high energy band observed in the compounds 1 to 6 according to the present invention was also observed in the free L1 and L2, which is an extended aromatic system of the dipyridyl ligand conserved during self-assembly It suggests that transitions occur for the aromatic system.
- Dinuclear arene-Ru acceptors also have slightly higher energy absorption bands at 250-300 nm, and donor spacers of A3 also generate broadly low energy absorption bands from ⁇ 400 to 550 nm. Confirmed.
- a suitable single crystal of Compound 1 for X-ray analysis using synchrotron radiation is a slow vaporization of diethyl ether in a methanol solution of Compound 1 Obtained by vapor diffusion.
- Compound 1 has a tetranuclear rectangular architecture in the result of single crystal X-ray diffaction analysis, and lies in a crystallographic inversion center. It was confirmed.
- Human gastric cancer cell line AGS and human colon cancer cell line HCT15 were obtained from the American Type Culture Collection (Manassas, VA). All cells were cultured in a medium containing 5% fetal bovine serum (FBS) (RPMI 1640 medium) in the presence of 5% CO 2 at 37 °C.
- FBS fetal bovine serum
- IC 50 values are shown in Table 2 below compared to known anti-tumor drugs cisplatin and doxorubicin.
- HCT-15 cells were cultured in 75-cm 2 culture flasks at 37 ° C., 95% humidity, 5% CO 2 .
- Polyvinylidene fluoride (HFs) with a 1-mm internal diameter and a molecular weight cutoff point of 500 kDa (Spectrum Laboratories, Houston, TX, USA) were used. Sterilized HFs were washed with normal growth media before filling HCT-15 cells at a density of 5 ⁇ 10 5 cells / mL.
- Each fiber was heat sealed at a spacing of 1.5 cm with a hot smooth-jawed needle holder and cut into 2-mm tailed segments for ease of handling.
- Each HFs segment contained about 10 5 cells. The prepared HFs segments were maintained for 24 hours in vitro under normal growth conditions prior to injection.
- mice All animals were fed with water and food (Purina 5001 Rodent Chow; Purina, St. Louis, MO, USA) following 12 h light-dark cycles. Mice were anesthetized using Zoletil and Rompun. HFs were implanted subcutaneously (subcutaneou, s.c.) and peritoneal (i.p.) of anesthetized mice and sutured with skin staples.
- mice Two days later, male mice were fed using gavage at 100 mg / kg of body weight for 7 days. Mice were administered 100 ⁇ g kg ⁇ 1 bw / day of compound 3 and 6 for 7 days each.
- HFs were transferred to 0.5 ml of ethylenediaminetetraacetic acid (EDTA), cut in half in the longitudinal direction with a scalpel and washed with EDTA solution for 3 minutes. After washing for 5 minutes with 0.5 ml of trypsin, it was washed for 3 minutes with medium.
- EDTA ethylenediaminetetraacetic acid
- the compound 3 and 6 according to the present invention inhibited the proliferation of tumor cells in the IP region, the growth inhibitory effect by the compound 3 is 14.2%, the growth inhibitory effect by the compound 6 is 21.8% Was observed.
- the growth inhibitory effect by Compound 3 was 7.9%, and the growth inhibitory effect by Compound 6 was 8.5%, which is lower than that of the IP region.
- HCT-15 cells were labeled with 0.05 mM MDC (Sigma) in PPM1640 medium for 10 minutes at 37 ° C. After incubation, cells were washed three times with phosphate buffer salt and immediately using a fluorescence microscope (Nikon Eclipse TE 300, Japan) equipped with a filter system (V-2A excitation filter: 380/420 nm, barrier filter: 450 nm). The analysis was carried out. Field of vision and fluorescence images were taken with a digital camera (DP30BW; Olympus).
- Donor compound 7 was synthesized in the same manner as in Scheme 2 below.
- 3,6-dibromophenanthrene (89.6 mg, 0.267 mmol), 3-ethynylpyridine (63.3 mg, 0.613 mmol), CuI (2.5 mg, 0.013 mmol), [PdCl 2 (PPh 3 ) 2 ] (11.2 mg, 0.016 mmol), and PPh 3 (4.2 mg, 0.016 mmol) were placed in a round bottom flask and THF (5 mL) and triethylamine (5 mL) were added and bubbled with N 2 for 10 minutes.
- donor compound 7 and arene-Ru (II) receptors 8, 9 and 10 were respectively added and stirred at room temperature for 6 hours to obtain a clear solution.
- Diethyl ether was added dropwise to the solution to form a precipitate. The precipitate was washed twice with diethyl ether, centrifuged and dried to crystalline powder to give pure molecular bows 11-13.
- Phenanthrene donor 7 (Compound 7; 1.14 mg, 0.003 mmol) and Receptor 8 (2.72 mg, 0.003 mmol) were self-assembled in the same manner to obtain Molecular Ball 11 (Compound 11) as a dark red crystalline powder. (Yield 92%, see FIG. 9)
- Phenanthrene donor 7 (Compound 7; 1.14 mg, 0.003 mmol) and Receptor 9 (2.87 mg, 0.003 mmol) were self-assembled in the same manner to obtain Molecular Ball 12 (Compound 12) as a green crystalline powder. 90% yield)
- Phenanthrene donor 7 (Compound 7; 1.14 mg, 0.003 mmol) and Receptor 10 (3.17 mg, 0.003 mmol) were self-assembled in the same manner to obtain Molecular Ball 13 (Compound 13), which is a dark green crystalline powder. (Yield 94%)
- novel compound 11-13 synthesized by the above method was characterized by 1 H and 13 C NMR, electrospray ionization mass spectrometry (ESI-MS) and component analysis, and the solid state structure of complex 5 was determined by single crystal X-ray. Confirmed by analysis.
- the ⁇ -pyridyl proton of donor 7 was shifted 0.4-0.6 ppm upfield as it complexed with the receptors 8-10, and the 1 H NMR peak associated with the phenanthrene unit was also significantly upfield shifted.
- electrospray ionization mass spectrometry showed that the isotope distribution peaks of compounds 11, 12, and 13 were found at m / z 709.32, 742.96 and 809.49, respectively, and were consistent with their respective [M-3OTf] 3+ . The results were found to be identical to the theoretical isotope distribution pattern of compounds 11-13.
- PAL Pohang Accelerator Laboratory
- the average Ru-N pyridine band distance was 2.11 Hz, which was found to be similar to other tetranuclear structures.
- Human colon cancer cell HCT-15, human liver cancer cell SK-hep-1, human gastric cancer cell AGS and monkey fibroblast COS-7 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). HCT-15, AGS, and COS-7 cells in Dulbecco 'modified Eagle' medium (DMEM) and SK-hep-1 cells in 5% fetal bovine serum and 1% penicillin / streptomycin in RPMI 1640 medium. Incubated at 37 ° C., 5% CO 2 .
- DMEM Dulbecco 'modified Eagle' medium
- SK-hep-1 cells in 5% fetal bovine serum and 1% penicillin / streptomycin in RPMI 1640 medium. Incubated at 37 ° C., 5% CO 2 .
- Each cell was aliquoted into a 96-well plate and incubated overnight at 37 ° C. Thereafter, the cells were treated with each compound for a predetermined time period, and then cultured, and then treated with 10 ⁇ L of a 3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide (MTT) solution 37 Incubated for 4 hours at 5 °C CO 2 .
- MTT 3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide
- Formazan formed during the incubation period was dissolved by treatment with 100 ⁇ L DMSO and absorbance was measured at 550 nm with a microplate reader.
- Half-maximal inhibitory concentration (IC 50 ) values for cell growth were determined by fitting a plot of the percentage of viable cells to the log of drug concentration using a linear regression function.
- Apoptosis analysis was performed using a Tali ® Image-Based Cytometer (Invitrogen).
- AGS and COS-7 cells were treated with Compound 12 at 0-20 ⁇ M concentration and incubated at 37 ° C., 5% CO 2 for 24 hours. Thereafter, the number of cells was measured using a Countess ® Automated Cell Counter. Cells were harvested with TrypLE TM reagent and stained with Tali ® apoptosis kit.
- Oh apoptosis was dyed sheath cells to confirm apoptosis in Oh annexin V-Alexa Fluor ® 488 conjugate, was used for propidium iodide (PI) to distinguish dead cells.
- Percentages of live, apoptotic and dead cells according to the Tali ® analyzer were compared with the data obtained from the flow cytometer, respectively, using the same sample.
- the cultured cells were washed with cold PBS and lysed with RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) to obtain protein extracts. Protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, Calif., USA). Was measured.
- Bovine serum albumin (BSA) was used as the standard curve, and each protein was digested by the same amount (20 ⁇ g) by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). . Thereafter, it was transferred to an immobilon ® -P polyvinylidene difluoride membrane (Amersham, Arlington Heights, IL, USA) and incubated with primary antibody overnight.
- AGS cells were dispensed into 96-well plates with a clear bottom.
- Caspase-3 activity was measured using Caspase-Glo_3 Assay kit (CG3 kit, Promega, Mannheim, Germany) according to the manufacturer's instructions.
- CG3 analysis is a method of analyzing a luminescence signal generated by cleaving a specific sequence of a light-generating substrate by caspase-3, and fluorescence emission is 485 nm excitation wavelength using Mikrowin 2000 Plate Reader (Tecan, Switzerland). And 527 nm emission wavelength.
- donor 7 and compound 11-13 showed a strong anticancer effect in all cells as shown in Table 3.
- the IC 50 value of AGS cells treated with Compound 6 was 3.2 times lower than doxorubicin.
- Cisplatin (ICsplatin) showed an IC 50 value at a concentration of 100 ⁇ M or more in AGS cells, compared with other cells was found to have the lowest anti-cancer effect in gastric cancer.
- the AGS cell line which is a human gastric cancer cell, was selected to further analyze the anticancer ability of compounds 11-13.
- IC 50 concentration of drug required to inhibit 50% of cell viability
- Green fluorescent protein (GFP) -transduced cells were stained using the Tali ® Viability Kit, and dead cells of AGS gastric cancer cells and COS-7 normal monkey kidney fibroblasts were stained red.
- the self-extinguishing activity of AGS cells was significantly increased to 27.1, 48.6 and 68.4% in the cell group treated with Compound 12 at 5, 10 and 20 ⁇ M concentrations, respectively, compared to the untreated cell group.
- COS-7 cells which are normal cells, also increased autodigestion activity by 12.5, 18.9, and 23.3%, respectively, compared to untreated cells.
- the p62 protein that binds to the LC3 protein is generally a marker used to assess autophagic flux, in which expression is reduced during autophagy and accumulation of p62 protein is induced during autophagy.
- LC3 which plays an important role in the formation of autodigestion vesicles, is divided into two types, the cytoplasmic LC3-I and the membrane-bound LC3-II. In particular, the conversion of LC3-I to LC-II is increased during the autophagy.
- Akt-mTOR signaling pathway In human cancers, activation of Akt-mTOR signaling pathway through phosphorylation leads to proliferation and metastasis of cancer cells, whereas inhibition of Akt-mTOR signaling pathway is associated with autophagy inhibition because it activates autophagy.
- caspase-3 activity was confirmed through substrate cleavage reaction analysis.
- caspase-3 activity was increased in a concentration-dependent manner in the compound 12 treated cells as shown in FIG.
- Compound 12 induces cancer cell death by inhibiting the Akt / mTOR signaling pathway and activating autophagy.
- Compound 12 was treated with DMSO and culture medium (10% fetal bovine serum in DMEM) under the same conditions to confirm the stability of Compound 12.
- Compound 12 was added to the culture medium and pre-cultured at 37 ° C. for varying times and added to AGS cells for incubation. Compound 12 was preincubated in DMSO under the same conditions as a control.
- Deuterated NMR solvents were purchased from the Cambridge Isotope Laboratory (Andover, MA, USA) and NMR spectra were obtained using a Bruker 300 MHz spectrometer.
- Ligand L4 was synthesized in the same manner as in the synthesis of ligand L3 using a mixture of 2-phenylbenzimidazole (294 mg, 1.515 mmol) and KOH (170 mg, 3.031 mmol) in dimethylformamide (DMF).
- Ligand L5 was synthesized in the same manner as in the synthesis of ligand L3 using a mixture of 2-phenylbenzimidazole (294 mg, 1.515 mmol) and KOH (170 mg, 3.031 mmol) in dimethylformamide (DMF).
- Ring metal ruthenium compounds 14 to 16 were synthesized by the following Scheme 5.
- the reaction mixture was stirred at ⁇ 65 ° C. for 12 hours and the reaction process was confirmed using TLC.
- biphasic phenylbenzimidazole derivative ligand L4 50 mg, 0.081 mmol was dissolved in fresh distilled methanol in a round bottom flask dried under nitrogen atmosphere.
- reaction mixture was stirred at ⁇ 65 ° C. for 12 hours and the reaction was confirmed using TLC, after complete conversion, the methanol was removed under reduced pressure and dried under vacuum.
- reaction mixture was stirred at ⁇ 65 ° C. for 12 hours and the reaction was confirmed using TLC, after complete conversion, the methanol was removed under reduced pressure and dried under vacuum.
- Benzimidazole-ruthenium 16 was identified through single crystal X-ray diffraction (XRD) analysis using a radio accelerator to understand the features, identification and coordination structure around the ruthenium metal.
- XRD X-ray diffraction
- a single crystal of suitable red-orange color was obtained in XRD through slow evaporation of the compound 16 methanol solution at room temperature for several days.
- the ruthenium (II) metal in the ruthenacycle was surrounded by a piano-stool structure containing C, N-chelate and chloride ligands and p-cymene moieties on both sides of the ligand. Interestingly, the two chloride ligands Located in the opposite direction, it was confirmed that each of the trans structure.
- the lutena cycle is C-H... Cl, C-H... ⁇ and C-H... It was confirmed that stability was increased by several strong and weak non-covalent bonds such as N.
- FBS heat-inactivated fetal bovine serum
- DMEM Dulbecco's Modified Eagle Medium
- Cell suspensions were dispensed in 96-well plates at 1 ⁇ 10 4 cells / well concentration and incubated for 24 hours, then each compound was treated at 0.8, 4, 20 and 100 ⁇ M concentrations for 24, 48 and 72 hours.
- MTT [3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide] solution was dissolved in phosphate buffered saline (PBS, pH 7.2) to 5 mg / mL and filtered with a 0.22 ⁇ m Millipore filter. It was.
- the percentage of cells that survived was calculated from the percentage of untreated cells.
- the half maximal inhibitory concentration (IC 50 ) for cell growth inhibition was calculated by approximating logarithmic ratio points of viable cells to logarithm of drug concentration.
- the IC 50 value was between 6.1-12.5, 7.6-23.7 and 11.1-26.6 ⁇ M for AGS, Sk-hep-1 and HCT-15 cells, respectively.
- ligand L3-L5 IC 50 values found to be between 9.1-67.2, 39.9-82.5 and 61.9-94.2 ⁇ M for AGS, Sk-hep-1 and HCT-15 cells, respectively. Excellent inhibitory effect was shown.
- AGS gastric cancer cells
- Gene expression analysis was performed using ACP-based differential display RT-PCR technique (GeneFishing DEG screening technology) to identify gene expression changes related to the growth inhibition effect of benzimidazole-ruthenium 15 in gastric cancer cells AGS.
- CDNA was synthesized with reagents of GeneFishing DEG Premix Kit (Seegene, Korea) except reverse transcriptase SuperScript II (Invitrogen, USA).
- RNA 3 ⁇ g of total RNA was mixed with 2 ⁇ L of 10 ⁇ M cDNA synthesis primer dT-ACP1 (Seegene, Korea) and DEPC treated water to a final volume of 9.5 ⁇ L.
- the mixture was incubated at 80 ° C. for 3 minutes and immediately placed on ice for 2 minutes and then centrifuged briefly.
- CDNA synthesis was performed at 42 ° C. for 90 minutes and the reaction was inactivated at 94 ° C. for 2 minutes. After incubation on ice for 2 minutes, the reaction was diluted 5-fold by addition of 80 ⁇ L distilled water.
- Loosening adjustment primer (Annealing control primer; ACP ) Polymerase chain reaction PCR )
- DEGs Differentially expressed genes
- PCR for the second template synthesis was performed in one cycle of incubation at 94 ° C for 5 minutes, 50 ° C for 3 minutes and 72 ° C for 1 minute.
- amplification was carried out in 40 cycles, such as denaturation at 94 ° C for 40 seconds, annealing at 65 ° C for 40 seconds, and extension at 40 ° C for 40 seconds, followed by 5 minutes at 72 ° C. PCR was performed under the conditions of the last expansion step.
- the PCR product obtained through the above process was separated using 0.5 ⁇ TAE buffer and 2% agarose gel, and the differently expressed cDNA bands were cut out of the gel and purified.
- Total RNA was extracted from AGS gastric cancer cells using PureLink TM RNA Mini Kit. Total RNA reverse transcription was performed in 20 ⁇ L volumes, including 1 ⁇ g total RNA, oligo (dT) primers, enzymes and buffers provided in PrimeScript II 1st strand cDNA Synthesis kit (Takara, Japan).
- Quantitative real-time PCR reaction was performed in MX3005P (Stratagene, USA), using the following primers.
- RPS21 5'-GCTGCTTCCTTTCTCTCTCTG-3 ', 5'- GCCTGTGACCTTGTCAACCT-3' and ⁇ -actin: 5'-GTCCACCGCAAATGCTTCTA-3 ', 5'-TGCTGTCACCTTCACCGTTC-3'
- the thermal cycling profile was followed by 40 cycles of 95 ° C. (30 seconds), 53 ° C. (60 seconds) and 72 ° C. (30 seconds) after a 10 minute preincubation step at 95 ° C.
- Relative quantitative evaluation of RPS21 gene level was performed by comparative CT (cycle threshold) method.
- H36 mitochondria (KJ994345.1) and ZAM115 mitochondria (KJ185427.1) were found to be genes expressed by ACP11, which also reduced expression in AGS treated with benzimidazole-ruthenium 15 compounds.
- the downregulated gene RPS21 is known to be a component of eukaryotic lysosomes and is associated with lysosomal protein SA (RPSA) in human cells.
- RPSA lysosomal protein SA
- RPSA is known as the non-integrin laminin receptor and is overexpressed on the surface of various cancer cells. Thus, RPSA is considered to play an important role in tumor progression.
- qRT-PCR was performed using mRNAs of benzimidazole-ruthenium 15 compound treated AGS cells.
- Cytokines are signaling molecules that play critical roles in many biological processes, such as cell growth, differentiation, gene expression, migration, inflammation, and immunity. During inflammatory reactions, macrophages play a role in activating and collecting cytokines, or directly It kills.
- arene-Ru derivatives can be used to directly regulate the cancer cell cycle, cytokines produced from these derivatives can indirectly affect cancer cells.
- 31 cytokines (TNF- ⁇ , IFN ⁇ , G-CSF, GM-CSF, IL-1 ⁇ , IL-8, IP-10, Rantes, VEGF, EGF, IL-6, Resistin, PAI-1, IL-12 , IL-13, Eotaxin-3, PDGF-BB, PIGF-1, ⁇ -NGF, SCF, MCP-1, MIP-1 ⁇ , IL-2, IL-4, IL-10, FGF ⁇ , Leptin, IGF-1
- benzimidazole-ruthenium 2 (10 ⁇ M) or nothing-treated culture medium was treated with THP-1 human mononuclear leukocytes for 24 hours and Human Cytokine The content of 31 cytokines was determined using an ELISA Plate Array I kit (Signosis, USA).
- the ELISA analysis was performed according to the manufacturer's instructions, and chemiluminescence detection was performed with a multi-reader.
- cytokine IFN ⁇ , IL-1 ⁇ , VEGF, EGF, Eotaxin-3, IL-10, TGF- ⁇ and IL-17 ⁇ were increased in AGS cells treated with 10 ⁇ M concentration of Compound 15 as shown in FIG.
- the secretion of vascular endothelial growth factor (VEGF) was 8.2-fold higher than that of the non-treated compound 15.
- cytokines known as central mediators of angiogenesis, were secreted more than three times in AGS cells treated with 10 ⁇ M concentration of Compound 15, and this result may be rather helpful for the growth of cancer cells.
- interleukin- ⁇ IFN ⁇
- IFN ⁇ interleukin- ⁇
- benzimidazole-ruthenium 2 was found to reduce the release of rantes and IGF-1 (insulin-like growth factor 1) in macrophages.
- Lante is highly expressed in various cancers to promote tumor growth and metastasis through cancer cell proliferation and angiogenesis, and IGF-1 has a strong effect at key stages of cancer development such as cancer cell proliferation, apoptosis, angiogenesis and metastasis .
- benzimidazole-ruthenium 15 reduced the lante and IGF-1 secretion of macrophage, while increasing the secretion of IFN ⁇ , thereby suppressing the growth of cancer cells.
- the growth inhibitory activity of benzimidazole-ruthenium 15 decreased by 50% after 32 hours of preculture in the cell culture medium.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne : un nouveau composé arène-ruthénium tétranucléaire et une composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif ; un nouveau composé de phénanthrène-ruthénium et une composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif ; et un nouveau composé de benzimidazole-ruthénium dérivé d'un dérivé benzimidazolyle, et une composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0191962 | 2014-12-29 | ||
KR1020140191962A KR101683350B1 (ko) | 2014-12-29 | 2014-12-29 | 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암 질환 예방 또는 치료용 약학 조성물 |
KR1020150100362A KR101744398B1 (ko) | 2015-07-15 | 2015-07-15 | 신규 페난트렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암질환의 예방 또는 치료용 약학조성물 |
KR10-2015-0100362 | 2015-07-15 | ||
KR1020150161880A KR101776412B1 (ko) | 2015-11-18 | 2015-11-18 | 신규 벤즈이미다졸-루테늄 화합물 및 이를 유효성분으로 함유하는 암질환의 예방 또는 치료용 약학조성물 |
KR10-2015-0161880 | 2015-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016108489A1 true WO2016108489A1 (fr) | 2016-07-07 |
Family
ID=56284576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/014074 WO2016108489A1 (fr) | 2014-12-29 | 2015-12-22 | Nouveau composé de ruthénium et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016108489A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440602A (zh) * | 2018-04-17 | 2018-08-24 | 深圳大学 | 四核铱配合物及其制备方法与应用 |
CN108689943A (zh) * | 2018-06-04 | 2018-10-23 | 江苏师范大学 | 含钌超分子化合物及其制备方法和应用 |
CN113387984A (zh) * | 2020-03-13 | 2021-09-14 | 九江学院 | 含去质子二甲双胍配体的对称双核钌配合物及其制备方法和应用 |
CN115925617A (zh) * | 2022-08-25 | 2023-04-07 | 中山大学·深圳 | 一种氘代钌配合物及其制备方法和在光催化抗肿瘤中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130029673A (ko) * | 2011-09-15 | 2013-03-25 | 울산대학교 산학협력단 | 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물 |
KR20130104239A (ko) * | 2012-03-13 | 2013-09-25 | 울산대학교 산학협력단 | 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물 |
-
2015
- 2015-12-22 WO PCT/KR2015/014074 patent/WO2016108489A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130029673A (ko) * | 2011-09-15 | 2013-03-25 | 울산대학교 산학협력단 | 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물 |
KR20130104239A (ko) * | 2012-03-13 | 2013-09-25 | 울산대학교 산학협력단 | 신규한 4핵 아렌-루테늄 화합물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (4)
Title |
---|
DINOLFO, PETER H. ET AL.: "Rhenium-based Molecular Rectangles as Fameworks for Ligand-centered mixed Valency and Optical Electron Transfer", J. AM. CHEM. SOC., vol. 126, 2004, pages 12898 - 13001 * |
KUEHL, CHRISTOPHER J. ET AL.: "Self-Assembly with Postmodification: Kinetically stabilized Metalla-Supramolecular Rectangles", J. AM. CHEM. SOC., vol. 123, 2001, pages 9634 - 9641 * |
SHANMUGARAJU, SANKARASEKARAN ET AL.: "Constructions of 2D-Metallamacrocycles using Half-Sandwich RuII2 Precursors: Synthesis, Molecular Structures, and Self-Selection for a Single Linkage Isomer", ORGANOMETALLIES, vol. 30, 2001, pages 1951 - 1960 * |
YELLOL, GORAKH S. ET AL.: "On the Antitumor Properties of Novel Cyclometalated Benzimidazole Ru(II), Ir(III) and RH(III) Complexes", CHEM. COMMUN., vol. 49, 2013, pages 11533 - 11535 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440602A (zh) * | 2018-04-17 | 2018-08-24 | 深圳大学 | 四核铱配合物及其制备方法与应用 |
CN108689943A (zh) * | 2018-06-04 | 2018-10-23 | 江苏师范大学 | 含钌超分子化合物及其制备方法和应用 |
CN108689943B (zh) * | 2018-06-04 | 2021-07-30 | 江苏师范大学 | 含钌超分子化合物及其制备方法和应用 |
CN113387984A (zh) * | 2020-03-13 | 2021-09-14 | 九江学院 | 含去质子二甲双胍配体的对称双核钌配合物及其制备方法和应用 |
CN113387984B (zh) * | 2020-03-13 | 2023-05-23 | 九江学院 | 含去质子二甲双胍配体的对称双核钌配合物及其制备方法和应用 |
CN115925617A (zh) * | 2022-08-25 | 2023-04-07 | 中山大学·深圳 | 一种氘代钌配合物及其制备方法和在光催化抗肿瘤中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016108489A1 (fr) | Nouveau composé de ruthénium et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif | |
WO2017188694A1 (fr) | Composé hétéroaryle comprenant de l'azote et son utilisation | |
WO2011083999A2 (fr) | Dérivé de biguanide, son procédé de préparation, et composition pharmaceutique contenant ce dérivé en tant que principe actif | |
WO2018004213A1 (fr) | Nouveau composé ayant une activité inhibitrice de smo et composition comprenant celui-ci en tant qu'ingrédient actif pour prévenir ou traiter le cancer | |
WO2021075691A1 (fr) | Dérivé de pyrimidine, son procédé de préparation, et composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que composant actif | |
WO2014109530A1 (fr) | Dérivé 2-(phényléthynyl)thiéno[3,4-b]pyrazine, et composition pharmaceutique comprenant ce dérivé et destinée à la prévention ou au traitement du cancer | |
WO2009125923A2 (fr) | Nouveaux dérivés de bispyridyl carboxamide d'acide indole carboxylique, leurs sels pharmaceutiquement acceptables, procédé de préparation et composition les contenant en tant d'ingrédient actif | |
WO2018012907A1 (fr) | Nouveaux dérivés de quinazolinone inhibant la pi3k et composition pharmaceutique en contenant | |
WO2016032209A2 (fr) | N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase | |
WO2021145655A1 (fr) | Nouveau dérivé de pyrazole | |
WO2020040582A1 (fr) | Nouveau dérivé de benzopyrane ou sel pharmaceutiquement acceptable de celui-ci et composition pharmaceutique le comprenant en tant que principe actif | |
WO2021125802A1 (fr) | Nouveau dérivé d'indazole et son utilisation | |
WO2016006975A2 (fr) | Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation | |
WO2018021826A1 (fr) | Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif | |
WO2016093554A2 (fr) | Nouveau dérivé de 4-(aryl)-n-(2-alkoxythiéno[3,2-b]pyrazin-3-yl)-pipérazine-1-carboxamide et effet antiprolifératif de celui-ci | |
WO2020096416A1 (fr) | Composé inhibant la liaison yap-tead et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé en tant que principe actif | |
WO2018164549A1 (fr) | Nouveau composé ayant une activité inhibitrice de malate déshydrogénase et composition pharmaceutique destinée à prévenir ou à traiter le cancer le contenant à titre de principe actif | |
WO2022103149A1 (fr) | Nouveau dérivé de carbazole et composition pharmaceutique pour la prévention ou le traitement du cancer le comprenant en tant que principe actif | |
WO2021230710A1 (fr) | Nouvel inhibiteur d'ido/tdo, son utilisation anticancéreuse, et polythérapie anticancéreuse associée | |
WO2022086110A1 (fr) | Dérivé de thiobenzimidazole ou sel pharmaceutiquement acceptable de celui-ci, et leur utilisation | |
WO2021149900A1 (fr) | Dérivé d'adamantyle disubstitué ou son sel pharmaceutiquement acceptable, et composition pharmaceutique pour empêcher la croissance du cancer le contenant comme principe actif | |
WO2021235813A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement du cancer du pancréas associé à une mutation ron et méthode l'utilisant | |
WO2021096314A1 (fr) | Nouveau dérivé de benzimidazole et son utilisation | |
WO2021101268A1 (fr) | Dérivé de benzamide, son procédé de préparation, et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer | |
WO2021137665A1 (fr) | Composé dérivé de 1,2,3-triazole utilisé en tant qu'inhibiteur de hsp90, et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15875583 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15875583 Country of ref document: EP Kind code of ref document: A1 |